BOOK
Autoimmune Diseases of the Skin, An Issue of Immunology and Allergy Clinics - E-Book
(2012)
Additional Information
Book Details
Abstract
This issue of Immunology and Allergy Clinics provides a comprehensive review of autoimmune skin diseases, including bullous pemphigoid, pemphigus vulgaris, linear IgA disease, dermatitis herpetiformis, blistering and bullous diseases.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Immunology and Allergy\rClinics of North America: Autoimmune Diseases of the Skin | i | ||
| Copyright Page | ii | ||
| Table of Contents | v | ||
| Contributors | iii | ||
| Foreword: Cutaneous Immunity and Autoimmunity | xi | ||
| REFERENCES | xii | ||
| Preface: Autoimmune Diseases of the Skin | xiii | ||
| Chapter 1. Pathogenesis of Bullous Pemphigoid | 207 | ||
| THE MAJOR PATHOGENIC ANTIGEN IN BP: TYPE XVII COLLAGEN (COL17) | 207 | ||
| IN VIVO STUDIES ON BP | 209 | ||
| STUDIES ON IGE ANTIBODIES AGAINST COL17 | 211 | ||
| SUMMARY | 213 | ||
| REFERENCES | 213 | ||
| Chapter 2. Clinical Features and Practical Diagnosis of Bullous Pemphigoid | 217 | ||
| EPIDEMIOLOGY | 218 | ||
| CLINICAL FEATURES | 218 | ||
| TRIGGER FACTORS AND ASSOCIATED DISEASES | 220 | ||
| TARGET ANTIGENS | 222 | ||
| DIAGNOSIS | 222 | ||
| REACTIVITY WITH BP180 AND BP230 IN INDIVIDUALS WITHOUT BP | 225 | ||
| DIFFERENTIAL DIAGNOSIS | 226 | ||
| PROGNOSIS AND MORTALITY | 226 | ||
| CONCLUDING REMARKS | 227 | ||
| REFERENCES | 227 | ||
| Chapter 3. Diagnosis and Clinical Features of Pemphigus Vulgaris | 233 | ||
| CLINICAL PRESENTATION OF PEMPHIGUS VULGARIS | 233 | ||
| EPIDEMIOLOGY | 234 | ||
| CLINICAL FEATURES | 234 | ||
| DIFFERENTIAL DIAGNOSIS | 235 | ||
| DIAGNOSIS | 237 | ||
| HISTOPATHOLOGY | 238 | ||
| DISEASE ACTIVITY CATEGORIZATION | 239 | ||
| ACKNOWLEDGMENTS | 240 | ||
| REFERENCES | 240 | ||
| Chapter 4. Linear IgA Disease: Clinical Presentation, Diagnosis, and Pathogenesis | 245 | ||
| DEFINITION | 245 | ||
| DEMOGRAPHICS AND GENETIC BACKGROUND | 245 | ||
| CLINICAL FEATURES | 246 | ||
| LAD: TRIGGERS AND DISEASE ASSOCIATIONS | 247 | ||
| CLINICAL COURSE AND PROGNOSIS | 248 | ||
| DIAGNOSIS | 248 | ||
| PATHOGENESIS | 249 | ||
| TARGET ANTIGENS | 250 | ||
| REFERENCES | 251 | ||
| Chapter 5. An Exception Within the Group of Autoimmune Blistering Diseases: Dermatitis Herpetiformis, the Gluten-Sensitive Dermopathy | 255 | ||
| SKIN SYMPTOMS AND DISEASE MANAGEMENT | 256 | ||
| DIAGNOSIS CONFIRMATION | 258 | ||
| OTHER ASSOCIATED DISEASES | 259 | ||
| GENETIC BACKGROUND AND FAMILY SCREENING | 259 | ||
| TREATMENT | 260 | ||
| DISEASE PATHOGENESIS: CLINICAL RELEVANCE | 260 | ||
| MANAGEMENT OF DH | 261 | ||
| REFERENCES | 261 | ||
| Chapter 6. Pathophysiology of Dermatitis Herpetiformis: A Model for Cutaneous Manifestations of Gastrointestinal Inflammation | 263 | ||
| CLINICAL PRESENTATION | 264 | ||
| HISTOLOGY AND IMMUNOPATHOLOGY | 264 | ||
| ASSOCIATED CONDITIONS | 265 | ||
| IMMUNOGENETICS | 265 | ||
| IMMUNOPATHOGENESIS | 266 | ||
| SUMMARY | 270 | ||
| REFERENCES | 270 | ||
| Chapter 7. Management of Dermatitis Herpetiformis | 275 | ||
| TREATMENT | 275 | ||
| SUMMARY | 278 | ||
| REFERENCES | 278 | ||
| Chapter 8. Corticosteroid Use in Autoimmune Blistering Diseases | 283 | ||
| PHARMACOLOGY OF CORTICOSTEROIDS | 283 | ||
| RESPONSIVENESS OF AIBD TO CORTICOSTEROIDS | 284 | ||
| MINIMIZING THE ADVERSE EFFECTS OF CORTICOSTEROID USE | 289 | ||
| EXPERT RECOMMENDATIONS | 292 | ||
| REFERENCES | 292 | ||
| Chapter 9. Azathioprine in the Treatment of Autoimmune Blistering Diseases | 295 | ||
| HISTORY OF AZATHIOPRINE | 295 | ||
| STRUCTURE AND METABOLISM | 295 | ||
| AZATHIOPRINE IN BULLOUS PEMPHIGOID | 297 | ||
| AZATHIOPRINE IN PEMPHIGUS | 297 | ||
| AZATHIOPRINE IN OTHER AUTOIMMUNE BLISTERING DISEASES | 299 | ||
| AZATHIOPRINE DURING PREGNANCY | 299 | ||
| SIDE EFFECTS OF AZATHIOPRINE | 301 | ||
| SUMMARY | 304 | ||
| REFERENCES | 304 | ||
| Chapter 10. Mycophenolate Mofetil for the Management of Autoimmune Bullous Diseases | 309 | ||
| REFERENCES | 312 | ||
| Chapter 11. Dapsone in the Management of Autoimmune Bullous Diseases | 317 | ||
| PEMPHIGUS | 317 | ||
| PEMPHIGOID | 318 | ||
| BULLOUS LUPUS ERYTHEMATOSUS | 319 | ||
| EPIDERMOLYSIS BULLOSA ACQUISTA | 319 | ||
| DERMATITIS HERPETIFORMIS | 319 | ||
| LINEAR IgA BULLOUS DERMATOSIS | 320 | ||
| SUMMARY | 320 | ||
| REFERENCES | 320 | ||
| Chapter 12. The Use of Intravenous Immunoglobulin in Autoimmune Bullous Diseases | 323 | ||
| INTRODUCTION TO IVIG | 324 | ||
| SUMMARY | 328 | ||
| REFERENCES | 329 | ||
| Chapter 13. Rituximab and its Use in Autoimmune Bullous Disorders | 331 | ||
| MECHANISM OF ACTION | 331 | ||
| DOSE AND ROUTE OF ADMINISTRATION | 332 | ||
| ADVERSE EFFECTS | 332 | ||
| USE IN AUTOIMMUNE BLISTERING DISEASES | 333 | ||
| SUMMARY | 335 | ||
| REFERENCES | 335 | ||
| Index | 339 |